PhosphoBLOCKER™，完美解決磷酸化條帶差問題

* 文末有干貨下載：《艾美捷-WB常見問題-50問.PDF》

我有一個做蛋白質磷酸化（信號通路）研究的朋友，他說：WB是條不歸路，WB難，磷酸化蛋白的WB更難！他曾創造過一個實驗室記錄，做了200多次磷酸化蛋白，出結果的只有60幾次，與理論一致的只有40次不到。他，曾崩潰過...

現實情況確實如此，內源性目的蛋白本身在細胞裂解物中表達豐度不高，而其磷酸化修飾的蛋白含量就更低了！即使用高濃度抗體，延長曝光時間，依舊很難獲得理想的效果。大多數市售的WB封閉劑（如牛奶，血清，BSA）雖然可以滿足阻斷膜上的未反應位點，減少檢測過程中非特異性抗體的數量，但它們并不是為了在印跡過程中保護磷蛋白抗原而設計的，本身含有磷酸化蛋白成分，因而并不能為磷酸化WB雪中送炭！

作為專業的生命科學醫藥原料供應商，艾美捷科技為您推薦：磷酸化抗體專用：封閉液與抗體稀釋液（二合一），讓悲劇不再發生！

*** 該產品僅用于科研實驗.

• PhosphoBlocker封閉液特點：

1. 與奶粉，血清，BSA相比，更卓越的封閉效果
2. 同時，可作為抗體稀釋液使用，無需單獨購買
3. 增強低水平的磷蛋白信號而不增加背景
4. 在Western Blot期間保留磷蛋白抗原
5. 易于使用的預混合干混合物

?

• PhosphoBlocker效果對比：

Fig. A549細胞裂解液，檢測磷酸化-p38蛋白.

• Cell也在用的磷酸化抗體專用封閉液：

Orthofer, Michael, et al. "Identification of ALK in Thinness."?Cell?181.6 (2020): 1246-1262.

【摘要】盡管世界大部分地區都存在同樣致肥的環境，但個體對體重增加的易感性存在相當大的差異。盡管許多研究都集中在確定肥胖的遺傳易感性，但我們在一個獨特的表型愛沙尼亞隊列中對代謝健康的瘦個體（全人群 BMI 譜的最低第 6 個百分位數）進行了 GWAS。我們發現間變性淋巴瘤激酶 (ALK) 作為候選瘦基因。在果蠅中，RNAi 介導的 Alk 敲低導致甘油三酯水平降低。在小鼠中，Alk 的基因缺失導致瘦弱的動物對飲食和瘦素突變引起的肥胖具有明顯的抵抗力。從機制上講，我們發現下丘腦神經元中的 ALK 表達通過交感神經控制脂肪組織脂肪分解來控制能量消耗。我們的遺傳和機制實驗將 ALK 鑒定為瘦身基因，該基因與抵抗體重增加有關。

更多已發表文章：

• Chan, T.Y. et al. (2021). TNK1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth. Nat Commun. 12(1):5337. doi: 10.1038/s41467-021-25622-3.
• Ito, S. et al. (2021). Enoxaparin promotes functional recovery after spinal cord injury by antagonizing PTPRσ. Exp Neurol. 340:113679. doi: 10.1016/j.expneurol.2021.113679.
• Tsuchiya, M. et al. (2021). Functional analysis of isoflavones using patient-derived human colonic organoids. Biochem Biophys Res Commun. 542:40-47. doi: 10.1016/j.bbrc.2021.01.021.
• Shimazaki, R. et al. (2021). Complement factor B regulates cellular senescence and is associated with poor prognosis in pancreatic cancer. Cell Oncol (Dordr). doi: 10.1007/s13402-021-00614-z.
• Okada, R. et al. (2021). Low magnetic field promotes recombinant human BMP-2-induced bone formation and influences orientation of trabeculae and bone marrow-derived stromal cells. Bone Rep. doi: 10.1016/j.bonr.2021.100757.
• Gong, Y. et al. (2020). Identification of PTPRσ-interacting proteins by proximity-labeling assay. J Biochem. doi: 10.1093/jb/mvaa141.
• Kushioka, J. et al. (2020). A novel negative regulatory mechanism of Smurf2 in BMP/Smad signaling in bone. Bone Res. doi: 10.1038/s41413-020-00115-z.
• Attili, I. et al. (2020). SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer. Transl Lung Cancer Res. 9(5):1810-1821. doi: 10.21037/tlcr-20-681.
• Kushioka, J. et al. (2020). The small compound, TD-198946, protects against intervertebral degeneration by enhancing glycosaminoglycan synthesis in nucleus pulposus cells. Sci Rep. 10(1):14190. doi: 10.1038/s41598-020-71193-6.
• Orthofer, M. et al. (2020). Identification of ALK in Thinness. Cell. 181(6):1246-1262.e22. doi: 10.1016/j.cell.2020.04.034.
• Osrodek, M. et al. (2020). Insulin Reduces the Efficacy of Vemurafenib and Trametinib in Melanoma Cells. Cancer Manag Res. 12:7231-7250. doi: 10.2147/CMAR.S263767.
• Chabloz, A. et al. (2020). Salmonella-based platform for efficient delivery of functional binding proteins to the cytosol. Commun Biol. 3(1):342. doi: 10.1038/s42003-020-1072-4.
• Williams, J.J.L. et al. (2020). Investigation of Novel Cavin-1/Suppressor of Cytokine Signaling 3 (SOCS3) Interactions by Coimmunoprecipitation, Peptide Pull-Down, and Peptide Array Overlay Approaches. Methods Mol Biol. 2169:105-118. doi: 10.1007/978-1-0716-0732-9_10.
• Orthofer, M. et al. (2020). Identification of ALK in Thinness. Cell. S0092-8674(20)30497-9. doi: 10.1016/j.cell.2020.04.034.
• Zeng, X. et al. (2020). Effect of Low Dose of Berberine on the Radioresistance of Cervical Cancer Cells via a PI3K/HIF-1 Pathway under Nutrient Deprived Conditions. Int J Radiat Biol. doi: 10.1080/09553002.2020.1770358.
• Koizumi, R. et al. (2020). Relationship between hemodynamic alteration and sympathetic nerve activation following a single oral dose of cinnamtannin A2. Free Radic Res. doi: 10.1080/10715762.2020.1759805.
• Nihei, Y. et al. (2019). Poly-glycine-alanine exacerbates C9orf72 repeat expansion-mediated DNA damage via sequestration of phosphorylated ATM and loss of nuclear hnRNPA3. Acta Neuropathol. doi: 10.1007/s00401-019-02082-0.
• Taniguchi, K. et al. (2019). α-Aminoisobutyric acid-containing amphipathic helical peptide-cyclic RGD conjugation as a potential drug delivery system for microRNA replacement therapy in vitro. Mol Pharm. doi: 10.1021/acs.molpharmaceut.9b00680.
• Serrano-Regal, M.P. et al. (2019). Oligodendrocyte Differentiation and Myelination Is Potentiated via GABAB Receptor Activation. Neuroscience. pii: S0306-4522(19)30488-9. doi: 10.1016/j.neuroscience.2019.07.014.
• Czyz, M. et al. (2019). Plasticity of Drug-Na?ve and Vemurafenib- or Trametinib-Resistant Melanoma Cells in Execution of Differentiation/Pigmentation Program. Journal of Oncology. 2019:1697913. doi: 10.1155/2019/1697913.
• Ashizawa, Y. et al. (2019). OLFM4 Enhances STAT3 Activation and Promotes Tumor Progression by Inhibiting GRIM19 Expression in Human Hepatocellular Carcinoma. Hepatology Communications. doi:10.1002/hep4.1361.
• Bertran-Alamillo, J. et al. (2019). AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy. Nat Commun. 10(1):1812. doi: 10.1038/s41467-019-09734-5.
• Mielczarek-Lewandowska, A. et al. (2019). 17-Aminogeldanamycin selectively diminishes IRE1α-XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAFV600E inhibitors in melanoma cells of different genetic subtypes. Apoptosis. doi: 10.1007/s10495-019-01542-y.
• Nakada, S. et al. (2019). Roles of Pin1 as a Key Molecule for EMT Induction by Activation of STAT3 and NF-κB in Human Gallbladder Cancer. Ann Surg Oncol. 26(3):907-917. doi: 10.1245/s10434-018-07132-7.
• Hartman, M.L. et al. (2019). Whole-exome sequencing reveals novel genetic variants associated with diverse phenotypes of melanoma cells. Mol Carcinog. 58(4):588-602. doi: 10.1002/mc.22953.
• Bemben, M.A. et al. (2019). Isoform-specific cleavage of neuroligin-3 reduces synapse strength. Mol Psychiatry. 24(1):145-160. doi: 10.1038/s41380-018-0242-y.
• Ohara, M. et al. (2018). Extracellular Vesicles from Amnion-Derived Mesenchymal Stem Cells Ameliorate Hepatic Inflammation and Fibrosis in Rats. Stem Cells Int. 2018:3212643. doi: 10.1155/2018/3212643.
• Heishima, K. et al. (2018). Short-Term Administration of Single-Agent Toceranib in Six Cases of Inoperable Massive Canine Hepatocellular Carcinoma. J Am Anim Hosp Assoc. doi: 10.5326/JAAHA-MS-6788.
• Rodriguez-Perez, A.I. et al. (2018). Angiotensin Type 1 Receptor Antagonists Protect Against Alpha-Synuclein-Induced Neuroinflammation and Dopaminergic Neuron Death. Neurotherapeutics. 15(4):1063-1081. doi: 10.1007/s13311-018-0646-z.
• Palomo-Guerrero, M. et al. (2018). Uridine-5'-Triphosphate Partially Blocks Differentiation Signals and Favors a more Repair State in Cultured rat Schwann Cells. Neuroscience. 372:255-265. doi: 10.1016/j.neuroscience.2018.01.010.

艾美捷-WB常見問題-50問

................................................................................................

看到這兒，您心動了嗎？馬上聯系小艾吧！

或者掃描下方二維碼，即可聯系您的專屬客服哦~

文章來源：磷酸化條帶差？那是沒有遇見它，PhosphoBLOCKER！

作為一家具有高端的技術實力、先進的經營管理水平和完善的市場銷售體系的生物高科技企業，總部位于武漢光谷高新技術開發區，服務面向全國。艾美捷科技是集進口試劑、實驗室耗材銷售、技術服務與合約開發為一體的專業化高科技公司，為用戶提供專業的前沿資訊、完備的產品、整合的解決方案，及優質的物流服務。

艾美捷科技與國內外優秀的生物試劑供應商優保持著密切的合作關系，目前已成為眾多國際知名品牌的中國總代理或一級代理，主要包括：AmyJet、AATBioquest、Abbexa、Abnova、Agrisera、Anogen、Atlas Antibodies、Biosensis、Biovision、BioVendor、CaissonLabs、Cell?Biolabs、Crystal Chem、Cytoskeleton、Demeditec、Duchefa、Epigentek、Equitech-Bio、EXBio、Fitzgerald、GeneCopoeia、HycultBiotech、Icosagen、ImmunoReagents、ImmunoStep、Jackson、LC Laboratories、LifeSensors、LigaTrap、Lumiprobe、Mabtech、Matreya、MyBiosource、NorgenBiotek、Origene、ProImmune、ProSpec、ScyTek、SolisBioDyne、SouthernBiotech、StressMarq、SySy、USBiological、TRC等，可以在短時間內為用戶提供專業的前沿資訊、完備的產品及物流服務。